H.C. Wainwright Global Life Sciences Conference onMarch 9, 2021 , available on-demand beginning at7.00 a.m. ET Barclays Global Healthcare Conference onMarch 10, 2021 , at7:30 a.m. ET
The Company presentations from both conferences will be available on the investor relations section of the Freeline website at Freeline.life. Senior management will also participate in virtual one-on-one meetings with investors at these conferences.
About
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. We use our proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. Freeline’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the
Contacts
Vice President Investor Relations & Corporate Communications
david.arrington@freeline.life
+1 (646) 668 6947
juliawilsonuk@gmail.com
+44 (0) 7818 430877
Source:
2021 GlobeNewswire, Inc., source